Epygenix Therapeutics has been acquired by Harmony Biosciences, a pharmaceutical company dedicated to developing and commercializing
innovative therapies for patients with rare neurological diseases. For more information on Harmony and the acquisition, please click here
The Argus Trial is continuing uninterrupted with Harmony Biosciences.
Clinical Trials
Epygenix Candidates in Clinical Trials
Our pipeline of candidates includes multiple innovative drugs at varying stages of development. Our lead investigational drug, EPX-100, is currently in a pivotal Phase 2 clinical trial for Dravet Syndrome (DS) and Phase 2 planning for Lennox-Gastaut Syndrome (LGS) is underway, with a projected launch date in 2023.
Learn more about a Phase 2 Study for Dravet syndrome
Learn more about our clinical program on clinicaltrials.gov